TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1531825

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 3893139

Group type: EXPERIMENTAL
Intervention: Topical 2% epinephrine applied twice daily for two weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral indomethacin 25 mg four times daily for one week
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Discontinuation of indomethacin treatment in patients receiving topical epinephrine
Number of subjects: 100
Study: 31025894

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation (1.5 g/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 29880209

Group type: EXPERIMENTAL
Intervention: Computerized rehabilitation training (Power‐Afa)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional speech therapy
Number of subjects: 32
Study: 27064493

Group type: EXPERIMENTAL
Intervention: Tai Chi group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional heart group
Number of subjects: 0
Study: 24771609

Group type: EXPERIMENTAL
Intervention: Rolofylline
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2033
Study: 22950816

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 20865676

Group type: EXPERIMENTAL
Intervention: L-arginine (8 g/day in two doses for 60 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Citrulline (3 g/day in one dose for 60 days)
Number of subjects: 30
Study: 19024260

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond self‐etch adhesive with acid etching for 20 seconds
Number of subjects: 125

Group type: COMPARATOR
Intervention: Clearfil SE Bond self‐etch adhesive without acid etching (control)
Number of subjects: 125
Study: 15871849

Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg daily (S)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fenofibrate 200mg daily (F)
Number of subjects: 2
Study: 12943890

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 10815407

Group type: EXPERIMENTAL
Intervention: Improved and standardized diagnostic imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early decision making in surgery and physical/occupational therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: More well-defined indication for surgery considering trauma type, biological age, and functional demands
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less stereotyped thinking in follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Controlled randomized trials
Number of subjects: 0
Study: 9038665

Group type: EXPERIMENTAL
Intervention: Nutri-drink (early enteral nutrition)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1950028

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 4 weeks
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 3 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: No antiulcer therapy for 3 months
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg bid for 6 months
Number of subjects: 178

Group type: COMPARATOR
Intervention: No antiulcer therapy for 6 months
Number of subjects: 178
Study: 29954354

Group type: EXPERIMENTAL
Intervention: Ulva L.L. extract
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 26857999

Group type: EXPERIMENTAL
Intervention: Community health worker-based intervention
Number of subjects: 806

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 806
Study: 25304934

Group type: EXPERIMENTAL
Intervention: Segmental epidural steroid injections (SESIs)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 63
Study: 22552602

Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-exposed group (n = 145)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Meningococcal polysaccharide vaccine (MPSV4) in PSV-exposed group (n = 142)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Quadrivalent meningococcal conjugate vaccine (MCV4) in PSV-naïve group (n = 163)
Number of subjects: 450
Study: 20377413

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 162 mg PRO 140 weekly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 324 mg PRO 140 biweekly
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 324 mg PRO 140 weekly
Number of subjects: 44
Study: 17855125

Group type: EXPERIMENTAL
Intervention: Prime2 with a stimulus onset asynchrony (SOA) of 200 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prime2 with a spatial separation of 0 minarc
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prime2 with a stimulus onset asynchrony (SOA) of 53 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prime2 with a spatial separation of 58 minarc
Number of subjects: 0
Study: 15944071

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment at acu‐points ST36, LI11, SP10, and GV14
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham acupuncture (placebo) treatment
Number of subjects: 10
Study: 12627358

Group type: EXPERIMENTAL
Intervention: Maximal sterile barrier precautions (SBPs) during arterial catheter insertion
Number of subjects: 373

Group type: COMPARATOR
Intervention: Standard-of-care group (control)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 373
Study: 10690148

Group type: EXPERIMENTAL
Intervention: Hanging Drop (HD) technique
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Loss of Resistance (LOR) technique
Number of subjects: 40
Study: 8708726

Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with etoposide (120 mg/m2 on days 1 and 3) and vindesine (3 mg/m2 on day 3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Induction chemotherapy with ifosfamide, etoposide, and an anthracycline (doxorubicin or epirubicin)
Number of subjects: 84
Study: 1914084

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBDCA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Iproplatin (CHIP)
Number of subjects: 89
Study: 6194944

Group type: EXPERIMENTAL
Intervention: Developmental education for parents
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Parent education in child management
Number of subjects: 39

Group type: COMPARATOR
Intervention: No-education control condition
Number of subjects: 39
Study: 29601220

Group type: EXPERIMENTAL
Intervention: Perceived force at 25% MVC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perceived force at 50% MVC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Perceived force at 75% MVC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Post-MVC performance
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Participants familiar with exercise
Number of subjects: 30
Study: 30019318

Group type: EXPERIMENTAL
Intervention: Panitumumab + FOLFOX4
Number of subjects: 528

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 528
Study: 26729381

Group type: EXPERIMENTAL
Intervention: Referral to weekly cardiac rehabilitation (CR) exercise classes and information sessions.
Number of subjects: 41
Study: 25073752

Group type: EXPERIMENTAL
Intervention: Combined introducer tool and stylet technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Digital manipulation technique
Number of subjects: 90

Group type: COMPARATOR
Intervention: Introducer tool technique
Number of subjects: 90
Study: 23115772

Group type: EXPERIMENTAL
Intervention: Rotary instruments
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 40
Study: 21173294

Group type: COMPARATOR
Intervention: 6 mL/kg/h of crystalloid (restrictive fluid strategy)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 12 mL/kg/h of crystalloid (conservative fluid strategy)
Number of subjects: 70
Study: 16278262

Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D doses of 1,400 IU (200 IU/d)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Weekly oral vitamin D doses of 14,000 IU (2,000 IU/d)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 179
Study: 14640932

Group type: EXPERIMENTAL
Intervention: Topical tazarotene monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies (with steroids, calcipotriene, and phototherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study: 11153016

Group type: EXPERIMENTAL
Intervention: SonoVue 0.5 ml
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SonoVue 1 ml
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SonoVue 2 ml
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SonoVue 4 ml
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SonoVue (all doses)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SonoVue
Number of subjects: 218
Study: 9160625

Group type: EXPERIMENTAL
Intervention: Major depression with lifetime panic disorder
Number of subjects: 276

Group type: COMPARATOR
Intervention: Major depression without lifetime panic disorder
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and psychotherapy
Number of subjects: 276
Study: 1423181

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Metoclopramide (1 mg/kg)
Number of subjects: 45
Study: 6229314

Group type: EXPERIMENTAL
Intervention: Health visitor intervention in urban practice
Number of subjects: 0
Study: 31818841

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention (8 weeks, 9 modules)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Active control condition with a self-help manual
Number of subjects: 352
Study: 29608839

Group type: EXPERIMENTAL
Intervention: Sulodexide treatment for 50 days
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no sulodexide)
Number of subjects: 52
Study: 25920633

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 30

Group type: COMPARATOR
Intervention: Corticosteroid (CS) injection
Number of subjects: 30
Study: 23633757

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST) combined with behavioral sleep strategies
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cognitive therapy (CT) combined with behavioral sleep strategies
Number of subjects: 47
Study: 20689448

Group type: EXPERIMENTAL
Intervention: SDT-based intervention
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Moderate and vigorous exercise at 2 yr
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: 2-yr autonomous regulation
Number of subjects: 221
Study: 20122585

Group type: EXPERIMENTAL
Intervention: A‐Line AEP (AAI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: aepEX
Number of subjects: 40
Study: 16950057

Group type: EXPERIMENTAL
Intervention: Marathon polyethylene liners (cross-linked with 5 Mrad gamma-irradiation and heat-treated)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enduron polyethylene liners (non-cross-linked)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marathon polyethylene liners (cross-linked)
Number of subjects: 0
Study: 15489865

Group type: EXPERIMENTAL
Intervention: Lenograstim (Granocyte)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12577369

Group type: EXPERIMENTAL
Intervention: Combination therapy of composite Shendi Decoction (CSDD) and Diyin Tablet (DYT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Composite Shendi Decoction (CSDD) alone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diyin Tablet (DYT) alone
Number of subjects: 35
Study: 9605804

Group type: EXPERIMENTAL
Intervention: Multivitamins
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1075
Study: 8029265

Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Tyrosine (150 mg/kg) at 22 degrees C
Number of subjects: 8
Study: 2557049

Group type: EXPERIMENTAL
Intervention: Tartar control dentifrice formulation containing soluble pyrophosphates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 0
Study: 4599121

Group type: EXPERIMENTAL
Intervention: Cephacetrile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 0
Study: 29342060

Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (HXLPE/VitE) cup
Number of subjects: 62

Group type: COMPARATOR
Intervention: Ultra-high molecular weight polyethylene (UHMWPE) cup
Number of subjects: 62
Study: 28153933

Group type: EXPERIMENTAL
Intervention: Usual care plus a falls prevention programme (video, workbook, individualised follow-up)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Usual care plus a social visit
Number of subjects: 390
Study: 26117292

Group type: EXPERIMENTAL
Intervention: UMEC 62.5 μg + FF/VI (100/25 μg)
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: UMEC 125 μg + FF/VI (100/25 μg)
Number of subjects: 1238

Group type: COMPARATOR
Intervention: Placebo + FF/VI (100/25 μg)
Number of subjects: 1238
Study: 23205521

Group type: EXPERIMENTAL
Intervention: Self-face prime condition (participants exposed to videos of their own faces)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonself-face prime condition (participants exposed to faces of others)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-face prime condition (participants with high autism traits)
Number of subjects: 0
Study: 21206307

Group type: EXPERIMENTAL
Intervention: Epidural motor cortex stimulation (MCS) with a new octopolar lead
Number of subjects: 6
Study: 18422412

Group type: EXPERIMENTAL
Intervention: Online family problem‐solving (OFPS) intervention
Number of subjects: 150

Group type: COMPARATOR
Intervention: Internet resource intervention (IRI)
Number of subjects: 150
Study: 16494632

Group type: EXPERIMENTAL
Intervention: Immediate PLLA treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Delayed PLLA treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (delayed treatment)
Number of subjects: 30
Study: 12621597

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 57
Study: 11780993

Group type: EXPERIMENTAL
Intervention: Lidocaine-containing bioadhesive patch (L-BP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Benzocaine-containing gel (B-G)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Needlestick injections with anesthetic
Number of subjects: 60

Group type: COMPARATOR
Intervention: 25- and 27-gauge needles
Number of subjects: 60
Study: 9440907

Group type: EXPERIMENTAL
Intervention: GH treatment (0.15 IU/kg/day s.c.) for 1 year
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 17
Study: 8493626

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms) inhaled four times daily for 24 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo inhaled four times daily for 24 weeks
Number of subjects: 64
Study: 3371081

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (550 mg initial dose, then 275 mg as needed, max 5 doses/day for 3 days)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dihydrocodeine tartrate (30 mg initial dose, then 30 mg as needed, max 5 doses/day for 3 days)
Number of subjects: 54
Study: 31691827

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29861241

Group type: EXPERIMENTAL
Intervention: Individual training sessions
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Group training sessions
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Training sessions (3rd, 4th, and 5th)
Number of subjects: 82
Study: 24237482

Group type: EXPERIMENTAL
Intervention: Healthy Relationships videoconferencing group intervention (HR-VG)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study: 22269534

Group type: EXPERIMENTAL
Intervention: 100 mg MDMA
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.42 mg/kg methamphetamine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 20039172

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 mg/day, uptitrated to 10 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 17362710

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (20 microg of ethinyl estradiol/100 mg of levonorgestrel)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 15952551

Group type: EXPERIMENTAL
Intervention: Brackets bonded 4 mm from the intact incisal edge
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bracket position determined individually by transferring the maximum embrasure difference to the bracket slot height difference
Number of subjects: 40
Study: 12221216

Group type: EXPERIMENTAL
Intervention: 10 g fructose fed 60 min before the potato meal
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 10 g fructose fed 30 min before the potato meal
Number of subjects: 31

Group type: COMPARATOR
Intervention: 50 g available carbohydrate from instant mashed potatoes (control)
Number of subjects: 31
Study: 9706927

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hypobaric bupivacaine (15 mg) with morphine sulfate (0.2 mg)
Number of subjects: 30
Study: 8581394

Group type: EXPERIMENTAL
Intervention: High dose chemotherapy with recombinant human GM-CSF (rhGM-CSF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard doses of chemotherapy without rhGM-CSF
Number of subjects: 12
Study: 2533678

Group type: EXPERIMENTAL
Intervention: Thymoxamine 0.5%
Number of subjects: 20
Study: 481976

Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg/kg intramuscularly during days 1 to 3 of life)
Number of subjects: 40
Study: 31151343

Group type: EXPERIMENTAL
Intervention: Percutaneous disc decompression with coblation nucleoplasty (PDCN)
Number of subjects: 74
Study: 27644475

Group type: EXPERIMENTAL
Intervention: Pomegranate extract (PE) 1000 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 19
Study: 26543359

Group type: EXPERIMENTAL
Intervention: Zabofloxacin (367 mg once daily for 5 days)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg once daily for 7 days)
Number of subjects: 345
Study: 23947742

Group type: EXPERIMENTAL
Intervention: PEMF therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21704212

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lifestyle therapy
Number of subjects: 0
Study: 20027368

Group type: EXPERIMENTAL
Intervention: Tenoten
Number of subjects: 0
Study: 17977787

Group type: EXPERIMENTAL
Intervention: H1-coil
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: H2-coil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard figure-8 coil
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham-coil control
Number of subjects: 32
Study: 16649053

Group type: EXPERIMENTAL
Intervention: Pressure dressing
Number of subjects: 96

Group type: COMPARATOR
Intervention: No dressing (exposed wounds)
Number of subjects: 96
Study: 12809167

Group type: EXPERIMENTAL
Intervention: Acylated ghrelin (1.0 microg/kg i.v. at 0 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Non-acylated ghrelin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 10528035

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for 52 weeks
Number of subjects: 143
Study: 7853592

Group type: EXPERIMENTAL
Intervention: Transabdominal incision (TAI)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Retroperitoneal incision (RPI)
Number of subjects: 145
Study: 1951300

Group type: EXPERIMENTAL
Intervention: Tranexamic acid administered pre-ECC
Number of subjects: 17

Group type: COMPARATOR
Intervention: Tranexamic acid administered post-ECC
Number of subjects: 17
Study: 6128875

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EAP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Traditional Manual Acupuncture (TMA)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEAP)
Number of subjects: 18
Study: 30658275

Group type: EXPERIMENTAL
Intervention: GermanIMPACT (intervention group)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 246
Study: 27951475

Group type: EXPERIMENTAL
Intervention: Sitting position during spontaneous breathing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Semirecumbent position during spontaneous breathing
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Supine position during spontaneous breathing
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mechanical ventilation (all positions)
Number of subjects: 9
Study: 25133646

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) twice a week
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) whole week
Number of subjects: 80
Study: 23083416

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intervention (MI)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 142
Study: 21166843

Group type: EXPERIMENTAL
Intervention: HbA(1c) ≥ 6.5% (≥ 48 mmol/mol)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: HbA(1c) ≥ 6.0% (≥ 42 mmol/mol)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Diagnosis based on two consecutive oral glucose tolerance tests
Number of subjects: 522
Study: 18058810

Group type: EXPERIMENTAL
Intervention: Topotecan with thalidomide (200 mg/day, increased as tolerated)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Topotecan alone
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Topotecan with thalidomide
Number of subjects: 69
Study: 16925692

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (80/4.5 microg, two inhalations twice daily)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Budesonide (100 microg, two inhalations twice daily)
Number of subjects: 630

Group type: COMPARATOR
Intervention: Budesonide (100 microg, two inhalations twice daily) and formoterol (4.5 microg, two inhalations twice daily) in separate inhalers
Number of subjects: 630